https://www.selleckchem.com/pr....oducts/Romidepsin-FK
There are limited data on the efficacy and tolerability of VCD chemotherapy in transplant-non-eligible (TNE) newly diagnosed myeloma (NDMM) patients. In this retrospective study, we set out to evaluate this triplet combination in this setting across Thames Valley Cancer Network (UK). The primary end point was overall response rate (ORR). Secondary outcomes included event-free survival (EFS), overall survival (OS) and adverse events (AEs). In a total cohort of 158 patients, ORR for total cohort was 72.1%. Median EFS was 10.5mont
Like
Comment
Share
